Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Clinically apparent long-term electric disturbances in the acute and very long-term of patent foramen ovale device-based closure.

Rigatelli G, Zuin M, Pedon L, Zecchel R, Dell'Avvocata F, Carrozza A, Zennaro M, Pastore G, Zanon F.

Cardiovasc Revasc Med. 2017 Mar;18(2):118-122. doi: 10.1016/j.carrev.2016.10.008. Epub 2016 Oct 29.

PMID:
27847261
2.

Long-Term Outcomes and Complications of Intracardiac Echocardiography-Assisted Patent Foramen Ovale Closure in 1,000 Consecutive Patients.

Rigatelli G, Pedon L, Zecchel R, Dell'Avvocata F, Carrozza A, Zennaro M, Mazza A, Zuin M, Russo M, Zanchetta M.

J Interv Cardiol. 2016 Oct;29(5):530-538. doi: 10.1111/joic.12325. Epub 2016 Aug 8.

PMID:
27500752
3.

The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.

Aral M, Mullen M.

Catheter Cardiovasc Interv. 2015 May;85(6):1058-65. doi: 10.1002/ccd.25750. Epub 2014 Nov 27.

PMID:
25413379
4.

Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.

Fischer D, Haentjes J, Klein G, Schieffer B, Drexler H, Meyer GP, Schaefer A.

J Interv Cardiol. 2011 Feb;24(1):85-91. doi: 10.1111/j.1540-8183.2010.00593.x. Epub 2010 Aug 23.

PMID:
20735710
5.

Comparison of residual shunt rates in five devices used to treat patent foramen ovale.

Matsumura K, Gevorgyan R, Mangels D, Masoomi R, Mojadidi MK, Tobis J.

Catheter Cardiovasc Interv. 2014 Sep 1;84(3):455-63. doi: 10.1002/ccd.25453. Epub 2014 Mar 4.

PMID:
24550064
6.

Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.

Susuri N, Obeid S, Ulmi M, Siontis GCM, Wahl A, Windecker S, Nietlispach F, Meier B, Praz F.

EuroIntervention. 2017 Sep 20;13(7):858-866. doi: 10.4244/EIJ-D-17-00061.

7.

Transcatheter patent foramen ovale closure is effective in reducing migraine independently from specific interatrial septum anatomy and closure devices design.

Rigatelli G, Cardaioli P, Dell'Avvocata F, Giordan M, Braggion G, Chinaglia M, Roncon L.

Cardiovasc Revasc Med. 2010 Jan-Mar;11(1):29-33. doi: 10.1016/j.carrev.2008.04.002.

PMID:
20129358
8.

Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II Occluder.

Neuser J, Akin M, Bavendiek U, Kempf T, Bauersachs J, Widder JD.

BMC Cardiovasc Disord. 2016 Nov 10;16(1):217.

9.

Clinical evaluation of a novel occluder device (Occlutech) for percutaneous transcatheter closure of patent foramen ovale (PFO).

Krizanic F, Sievert H, Pfeiffer D, Konorza T, Ferrari M, Figulla HR.

Clin Res Cardiol. 2008 Dec;97(12):872-7. doi: 10.1007/s00392-008-0699-9. Epub 2008 Aug 11.

PMID:
18696022
10.
11.

Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results.

Aytemir K, Oto A, Özkutlu S, Canpolat U, Kaya EB, Yorgun H, Şahiner L, Sunman H, Ateş AH, Kabakçı G.

Congenit Heart Dis. 2013 Sep-Oct;8(5):418-27. doi: 10.1111/chd.12057. Epub 2013 Apr 22.

PMID:
23601507
12.

Safety and efficacy of Cardi-O-fix occluder for percutaneous closure of a patent foramen ovale: A single-center prospective study.

Zhao E, Liu W, Zhang Y, Cheng G, Du Y, He L, Wang X, He X.

Medicine (Baltimore). 2017 Apr;96(14):e6572. doi: 10.1097/MD.0000000000006572.

13.

Transseptal puncture to facilitate device closure of "long-tunnel" patent foramen ovale.

Thompson AJ, Hagler DJ, Taggart NW.

Catheter Cardiovasc Interv. 2015 May;85(6):1053-7. doi: 10.1002/ccd.25723. Epub 2014 Nov 21.

PMID:
25380406
14.

Long-Term Contrast Echocardiography and Clinical Follow-Up after Percutaneous Closure of Patent Foramen Ovale Using Two Different Atrial Septal Occluder Devices.

Scalise F, Auguadro C, Sorropago G, Sorropago A, Novelli E, Finizio M, Specchia G.

J Interv Cardiol. 2016 Aug;29(4):406-13. doi: 10.1111/joic.12314. Epub 2016 Jun 24.

PMID:
27338839
15.

Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study.

Hammerstingl C, Bauriedel B, Stüsser C, Momcilovic D, Tuleta I, Nickenig G, Skowasch D.

Eur J Med Res. 2011 Jan 27;16(1):13-9.

16.

Percutaneous closure of the patent foramen ovale using the HELEX® Septal Occluder: acute and long-term results in 405 patients.

Heinisch C, Bertog S, Wunderlich N, Majunke N, Baranowski A, Leetz M, Fischer E, Staubach S, Zimmermann W, Hofmann I, Sievert H.

EuroIntervention. 2012 Oct;8(6):717-23. doi: 10.4244/EIJV8I6A111.

17.

Patent foramen ovale closure with the Gore septal occluder: initial UK experience.

Thomson JD, Hildick-Smith D, Clift P, Morgan G, Daniels M, Henderson R, Spence MS, Mahadevan VS, Crossland D, Ormerod O.

Catheter Cardiovasc Interv. 2014 Feb 15;83(3):467-73. doi: 10.1002/ccd.25063. Epub 2013 Sep 18.

PMID:
23766247
18.

Premere occlusion system for transcatheter patent foramen ovale closure: mid-term results of a single-center registry.

Rigatelli G, Cardaioli P, Dell'avvocata F, Giordan M, Chinaglia M.

Catheter Cardiovasc Interv. 2011 Mar 1;77(4):564-9. doi: 10.1002/ccd.22713.

PMID:
20602480
19.

Results of percutaneous closure of patent foramen ovale with the GORE(®) septal occluder.

Knerr M, Bertog S, Vaskelyte L, Hofmann I, Sievert H.

Catheter Cardiovasc Interv. 2014 Jun 1;83(7):1144-51. doi: 10.1002/ccd.25336. Epub 2014 Jan 20.

PMID:
24323667
20.

Using the GORE® Septal Occluder (GSO) in challenging patent foramen ovale (PFO) anatomies.

Geis NA, Pleger ST, Katus HA, Hardt SE.

J Interv Cardiol. 2015 Apr;28(2):190-7. doi: 10.1111/joic.12181. Epub 2015 Mar 2.

PMID:
25728716

Supplemental Content

Support Center